SPRY1 and breast carcinoma: Implicating the urokinase-type plasminogen activator receptor (uPAR) as a partner protein interacting with hSpry1 [145], Mekkawy et al. reported that hSpry1 colocalizes with uPAR upon stimulation with EGF and urokinase-type plasminogen activator (uPA), and suppresses uPAR-mediated migration and invasion of the MDA-MB-231 breast cancer cells [59].